Research Reports on Cutaneous Leishmaniasis from Federal University Rio de Janeiro Provide New Insights (Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis).

RIO de Janeiro (Brazil); BRAZIL

A new report from researchers at Federal University Rio de Janeiro in Brazil explores the use of crosslinked chitosan microparticles (CCM) as a safe and effective carrier for intranasal vaccination against cutaneous leishmaniasis. The study found that CCM, when used to deliver DNA encoding the leishmanial antigen LACK, induced protective immunity against both cutaneous and visceral leishmaniasis in rodents. The microparticles were shown to be mucoadherent and mucopenetrant, causing no local inflammation. Mice given the LACK DNA/CCM vaccine had significantly lower parasite loads and increased Th1-biased immune responses compared to those given naked LACK DNA or CCM alone. These findings suggest that CCM could enhance the efficacy of intranasal DNA vaccination against cutaneous leishmaniasis. [Extracted from the article]

Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)